Ads
related to: darzalex faspro patient information system- Prescribing Information
DARZALEX® Dosing
Information for Your Patients
- NCCN Recommendations
See the NCCN Recommendations
at the Official HCP Site
- Prescribing Information
Search results
Results From The WOW.Com Content Network
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]
It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]
The Patient-Reported Outcomes Measurement Information System [1] (PROMIS) provides clinicians and researchers access to reliable, valid, and flexible measures of health status that assess physical, mental, and social well–being from the patient perspective. PROMIS measures are standardized, allowing for assessment of many patient-reported ...
COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 11,670 million in 2024.
For premium support please call: 800-290-4726 more ways to reach us
Such systems are part of an overall information system and may interact with the person's electronic health record, [1] where information specific to the person is stored, the system used by radiology departments to track patients as well as the system storing medical images, the pathology laboratory information management system, as well as ...
Ads
related to: darzalex faspro patient information system